Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Penpulimab→

Penpulimab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2350298-92-7
Molecular formula
C6434H9922N1718O2012S46
Molecular weight
145007 g/mol
Drug class
Programmed cell death protein 1 (PD-1)-blocking monoclonal antibodyimmune checkpoint inhibitor
Mechanism of action
Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, relieving PD-1-mediated inhibitory signalling and restoring antitumour T-cell activity.
Indications / reported uses
  • In combination with gemcitabine and cisplatin or carboplatin for first-line treatment of adults with recurrent or metastatic non-keratinising nasopharyngeal carcinoma.
  • As monotherapy for adults with metastatic non-keratinising nasopharyngeal carcinoma that has progressed on or after platinum-based chemotherapy and at least one other prior line of therapy, under the US indication.

Sources: https://www.fda.gov/drugs/cancer-approvals/fda-approves-penpulimab-kcqx-non-keratinizing-nasopharyngeal-carcinoma · https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761258s002lbl.pdf

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Programmed cell death protein 1 (PD-1)-blocking monoclonal antibody; immune checkpoint inhibitor

Mechanism of action

Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, relieving PD-1-mediated inhibitory signalling and restoring antitumour T-cell activity.

General use cases

  • In combination with gemcitabine and cisplatin or carboplatin for first-line treatment of adults with recurrent or metastatic non-keratinising nasopharyngeal carcinoma.
  • As monotherapy for adults with metastatic non-keratinising nasopharyngeal carcinoma that has progressed on or after platinum-based chemotherapy and at least one other prior line of therapy, under the US indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Penpulimab Environmental Risk Assessment (ERA) (the Penpulimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.